Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination

Human Vaccines & Immunotherapeutics
Shinjiro SakamotoTetsuro Sasada

Abstract

Since cancer vaccines do not always elicit beneficial effects in treated patients, identification of biomarkers for predicting clinical outcomes would be highly desirable. We previously reported that abnormal granulocytes present in peripheral blood mononuclear cells (PBMC) may contribute to poor prognosis in advanced prostate cancer patients receiving personalized peptide vaccination (PPV). In the current study, we examined whether soluble factors derived from granulocytes, such as matrix metalloproteinase 9 (MMP-9), myeloperoxidase (MPO), and arginase 1 (ARG1), and inhibitory cytokine TGFβ in pre-vaccination plasma were useful for predicting prognosis after PPV in advanced cancer patients. In biliary tract cancer (n=25), multivariate Cox regression analysis demonstrated that patients with higher plasma MMP-9 levels had a significantly worse overall survival (OS) [hazard ratio (HR) = 4.637, 95% confidence interval (CI) = 1.670 - 12.877, P = 0.003], whereas MPO, ARG1, or TGFβ levels were not correlated with OS. Similarly, patients with higher MMP-9 levels showed worse prognosis than those with lower MMP-9 levels in other types of advanced cancers, including non-small cell lung cancer (n=32, P = 0.037 by log-rank test), and panc...Continue Reading

References

Oct 2, 2003·International Journal of Cancer. Journal International Du Cancer·Matthew G TuttonA Muti Abulafi
Aug 2, 2005·Nature Reviews. Immunology·Vincenzo Bronte, Paola Zanovello
Sep 21, 2006·Cancer Science·Kyogo Itoh, Akira Yamada
Aug 25, 2007·Cancer Metastasis Reviews·Michelle D Martin, Lynn M Matrisian
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mercedes N LópezFlavio Salazar-Onfray
Apr 24, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tetsuro SasadaKyogo Itoh
Jun 16, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aram F HezelAndrew X Zhu
Sep 10, 2010·Journal of the National Cancer Institute·Axel HoosJedd Wolchok
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mizuhiko TerasakiKyogo Itoh
Jan 12, 2011·Cancer Immunology, Immunotherapy : CII·Mary L Disis
May 3, 2011·Blood·Sally M AmosMichael H Kershaw
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianDrew M Pardoll
Dec 24, 2011·Nature·Ira MellmanGlenn Dranoff
Mar 8, 2012·Journal of the National Cancer Institute·Jeffrey Schlom
Jan 30, 2014·Cancers·Antonietta Rosella Farina, Andrew Reay Mackay
Feb 15, 2014·Current Medicinal Chemistry·Tetsuro SasadaKyogo Itoh
Feb 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonPaul A Bunn
Sep 11, 2014·The New England Journal of Medicine·David P RyanNabeel Bardeesy

❮ Previous
Next ❯

Citations

Mar 5, 2016·Expert Opinion on Biological Therapy·Shijoro SakamotoTetsuro Sasada

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

SAS
JMP

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.